<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89094">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974752</url>
  </required_header>
  <id_info>
    <org_study_id>D1344C00001</org_study_id>
    <nct_id>NCT01974752</nct_id>
  </id_info>
  <brief_title>Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)</brief_title>
  <acronym>SUMIT</acronym>
  <official_title>A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>France: *National Agency for the Safety of Medicine and Health Products.*</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Israel: *Regulations of Ministry of Health.*</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selumetinib therapy in patients with metastatic uveal melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised double-blind study to assess the efficacy of selumetinib (AZD6244, Hyd-Sulfate)
      in combination with Dacarbazine compared with placebo in combination with Dacarbazine as
      first systemic therapy in patients with metastatic uveal melanoma (SUMIT)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) by Blind Independent Central Review (BICR) according to RECIST 1.1</measure>
    <time_frame>Radiological scans performed from baseline then every 6 weeks until disease progression is confirmed by BICR in accordance with RECIST 1.1, assessed up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the efficacy of selumetinib in combination with dacarbazine with placebo in combination with dacarbazine in terms of PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by central review of RECIST data</measure>
    <time_frame>From baseline and at every 6 weeks, up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the efficacy of selumetinib in combination with dacarbazine with placebo in combination with dacarbazine by assessment of Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by central review of RECIST data.</measure>
    <time_frame>From baseline and at every 6 weeks, up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the efficacy of selumetinib in combination with dacarbazine with placebo in combination with dacarbazine by assessment of Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumour size by central review of RECIST data.</measure>
    <time_frame>From baseline and at every 6 weeks, up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the efficacy of selumetinib in combination with dacarbazine with placebo in combination with dacarbazine by assessment of change in tumour size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in patients by assessment of overall survival</measure>
    <time_frame>Post -progression patients assessed for survival every 8 weeks, up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess Overall survival in patients taking selumetinib in combination with dacarbazine compared with those taking placebo in combination with dacarbazine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety and tolerability of selumetinib by collection of adverse event reports</measure>
    <time_frame>From baseline and at each study visit up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine safety and tolerability of selumetinib by assessment of 12 lead electrocardiograms</measure>
    <time_frame>From baseline, up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of standard 12 lead electrocardiograms (ECGs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine safety and tolerability of selumetinib by assessment of vital signs</measure>
    <time_frame>From baseline and at each study visit up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of standard vital signs (including blood pressure, pulse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine safety and tolerability of selumetinib by assessment of clinical chemistry results</measure>
    <time_frame>From baseline and at each study visit up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of laboratory parameters (clinical chemistry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine safety and tolerability of selumetinib by assessment of haematology results</measure>
    <time_frame>From baseline and at each study visit up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of laboratory parameters (haematology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine safety and tolerability of selumetinib by assessment of urinalysis results</measure>
    <time_frame>From baseline and at each study visit up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of laboratory parameters (urinalysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine safety and tolerability of selumetinib by assessment of Echocardiogram/Multi gated Acquisition Scan (MUGA)</measure>
    <time_frame>From baseline and every 12 weeks up to 30 months.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of MUGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine safety and tolerability of selumetinib by Ophthalmologic assessment</measure>
    <time_frame>From baseline, up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Ophthalmological assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Metastatic</condition>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>selumetinib 75mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>selumetinib 75mg twice daily in combination with dacarbazine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo twice daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo twice daily in combination with dacarbazine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75mg selumetinib</intervention_name>
    <description>selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.</description>
    <arm_group_label>selumetinib 75mg twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.</description>
    <arm_group_label>placebo twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or  placebo tablets p.o. twice daily.</description>
    <arm_group_label>selumetinib 75mg twice daily</arm_group_label>
    <arm_group_label>placebo twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Clinical diagnosis of metastatic uveal melanoma; Written consent from
        female or male patients aged 18 years and over. Histological or cytological confirmation
        of melanoma who are suitable for treatment with dacarbazine chemotherapy.

          -  At least one lesion that can be accurately measured at baseline as&gt;/=10mm in the
             longest diameter.   (except lymph nodes which must have short axis ≥15 mm) with CT or
             MRI and which is suitable for accurate repeated measurements

          -  ECOG performance status 0-1

          -  life expectancy &gt;12 weeks

          -  Normal organ and marrow function

          -  Evidence of post-menopausal status, or negative urinary or serum pregnancy test for
             female pre-menopausal patients

          -  Patients should be able to swallow selumetinib/placebo capsules

        Exclusion Criteria:-Involvement in the planning and/or conduct of the study (applies to
        both AstraZeneca staff and/or staff at the study site)

          -  Previous randomisation in the present study

          -  Patients cannot have previously been treated with a systemic anti-cancer therapy.
             Patients can have prior intra-hepatic or non-systemic therapy. -Having received any
             of the following within the specified timeframe:

        Any prior systemic anti-cancer therapy for the treatment of this current diagnosis, An
        investigational drug within 30 days of starting treatment or within five half-lives of the
        compound (whichever is the most appropriate is at the discretion of the Investigator), or
        have not recovered from side effects of an investigational drug Any non-systemic
        anti-cancer therapy which has not been cleared from the body by the time of starting study
        treatment Radiation therapy within 4 weeks prior to starting study treatment, or limited
        field of radiation for palliation within 7 days of the first dose of study treatment Major
        surgery within 4 weeks prior to entry into the study (excluding the placement of vascular
        access) which would prevent administration of study treatment, Any prior investigational
        therapy comprising inhibitors of RAS, RAF or MEK at any time, Previous treatment with
        dacarbazine. Any unresolved toxicity &gt;CTCAE grade 2 from previous anti-cancer therapy,
        excluding alopecia -History of allergic reactions attributed to compounds of similar
        chemical or biologic composition to selumetinib or dacarbazine

        --Symptomatic brain metastases or spinal cord compression (patients must be treated and
        stable off steroids and anti-convulsants for at least 1 month prior to entry into the
        study)

        Cardiac conditions as follows:

          -  Uncontrolled hypertension (BP ≥150/95 mmHg despite medical therapy)

          -  Acute coronary syndrome within 6 months prior to starting treatment

          -  Uncontrolled Angina - Canadian Cardiovascular Society grade II-IV despite medical
             therapy - Symptomatic heart failure (New York Heart Association [NYHA] Class II-IV,-
             Prior or current cardiomyopathy

          -  Baseline LVEF &lt;55% measured by echocardiography or MUGA. Appropriate correction to be
             used if a MUGA is performed

          -  Severe valvular heart disease

          -  Atrial fibrillation with a ventricular rate &gt;100 bpm on ECG at rest

          -  QTcF &gt;450 ms or other factors that increase the risk of QTc prolongation

          -  Any evidence of severe or uncontrolled systemic disease, active infection, active
             bleeding diatheses or renal transplant, including any patient known to have hepatitis
             B, hepatitis C or human immunodeficiency virus (HIV)

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases (eg inflammatory
             bowel disease), or significant bowel resection that would preclude adequate
             absorption

          -  History of another primary malignancy within 5 years prior to starting study
             treatment, except for adequately treated basal or squamous cell carcinoma of the skin
             or cancer of the cervix in situ and the disease under study

          -  Ophthalmologic conditions:

          -  Current or past history of central serous retinopathy

          -  Current or past history of retinal vein occlusion

          -  IOP &gt;21 mmHg or uncontrolled glaucoma (irrespective of IOP)

          -  Female patients who are breast-feeding a child and male or female patients of
             reproductive potential who are not employing an effective method of birth control

          -  Clinical judgement by the Investigator that the patient should not participate in the
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ian Smith</last_name>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Darras</last_name>
    <email>nathalie.darras@quintiles.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveal melanoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
